Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study

Por Ardavanis, A, Tryfonopoulos, D, Alexopoulos, A, Kandylis, C, Lainakis, G, Rigatos, G
Publicado em 2005

Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negativeatients

Por Scorilas, A, Karameris, A, Arnogiannaki, N, Ardavanis, A, Bassilopoulos, P, Trangas, T, Talieri, M
Publicado em 2001

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre,...

Por Georgoulias, V, Kouroussis, C, Agelidou, A, Boukovinas, I, Palamidas, P, Stavrinidis, E, Polyzos, A, Syrigos, K, Veslemes, M, Toubis, M, Ardavanis, A, Tselepatiotis, E, Vlachonikolis, I
Publicado em 2004

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Por Mittendorf, E. A., Ardavanis, A., Symanowski, J., Murray, J. L., Shumway, N. M., Litton, J. K., Hale, D. F., Perez, S. A., Anastasopoulou, E. A., Pistamaltzian, N. F., Ponniah, S., Baxevanis, C. N., von Hofe, E., Papamichail, M., Peoples, G. E.
Publicado no Ann Oncol (2016)